SASogol Alikarami

Sogol Alikarami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sogol Alikarami has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Hamid Harandi

    School of Medicine Tehran University of Medical Sciences Tehran Iran

    2 shared publications
  • Ahmad Reza Dehpour

    Experimental Medicine Research Center, Tehran University of Medical Sciences

    1 shared publication
  • Ali Guermazi

    Department of Radiology, Boston Healthcare System, Boston University School of Medicine, Boston, MA, USA

    1 shared publication
  • Ali Jahanshahi

    School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

    1 shared publication
  • Ali Jahanshahi

    Social Determinants of Health Research Center, Trauma Institute Guilan University of Medical Sciences Rasht Iran

    1 shared publication
  • David J. Hunter

    Royal North Shore Hospital, Rheumatology, St Leonards, Australia; Sydney Musculoskeletal Health, Kolling Institute, University of Sydney, School of Medicine, Faculty of Medicine and Health, St Leonards, Australia

    1 shared publication

Latest Publications

  • MRI-defined tissue damage as predictors of the incidence and progression of knee osteoarthritis: A systematic review

    by Soheil Mohammadi, Hamid Harandi, Sogol Alikarami, Sajjad Fattahniya, Reza Samiee, Mohammad Ghavam, Elaheh Karimi, Ali Jahanshahi, Frank W. Roemer, David J. Hunter, et al.


  • High‐Intensity Focused Ultrasound in Treatment of Primary Breast Cancer: A Systematic Review and Meta‐Analysis

    by Sogol Alikarami, Hamid Harandi, Ali Jahanshahi, Seyed Sina Zakavi, Negin Frounchi, Mohammad Ghavam, Sara Momtazmanesh

    Background: In recent years, tumor management strategies have focused on less invasive methods, aiming to yield optimal efficacy while minimizing further complications and enhancing the overall outcome of patients. High‐intensity focused ultrasound (HIFU), a known thermal ablative technique, has shown promising results in breast cancer treatment. Therefore, we performed this systematic review and meta‐analysis to assess the clinical, histopathologic, immunologic, and radiologic outcomes of HIFU ablative therapy and its complications in patients with primary breast cancer. Methods: We searched PubMed and Scopus databases to identify the eligible articles. Data extraction was conducted by two independent authors. A random effects model was employed to pool the proportion of remaining tumor after HIFU therapy in breast cancer. A subgroup analysis was performed according to imaging guidance modality and study design. Moreover, the heterogeneity and bias were assessed using funnel plot, Egger's regression plot, and Baujat plot. Pooled CD4/CD8 ratio mean difference between HIFU and radical mastectomy was measured using a fixed‐effect model. Results: We included 26 studies and 677 participants in the systematic review. Tumor necrosis rates varied, with 4 studies reporting less than 50% complete necrosis and 5 more than 50%. Two studies observed HIFU‐induced disturbances in the microvasculature of the targeted tissue. Six noted no contrast enhancement in successfully treated areas, two observed a thin rim indicating necrosis or fibrosis, and four reported a persistent enhancement in MRI images associated with a residual viable tumor. The weighted proportion of patients with residual tumor was 0.59 (95% CI; 0.44–0.73). The subgroup analysis demonstrated that although the pooled proportion of ultrasound‐guided studies was notably higher than magnetic resonance imaging‐guided studies (0.71 vs. 0.57), the between‐group difference was not statistically significant ( p = 0.1693). The diagnostic tools showed that the results are driven by certain studies, and there is also a potential small‐study effect. Furthermore, the CD4/CD8 ratio was higher in the HIFU group, with a weighted mean difference of 0.6 (95% CI: 0.41–0.78). The most prevalent side effects were pain (47.14%) and skin burn (2.59%). Conclusions: HIFU is a relatively safe procedure for the treatment of breast cancer as an independent or conjugated therapy and its effectiveness is promising regarding histopathological response, immunological reactivity, and vascular damage in the targeted area.


  • Open Access

    A clinical presentation of rhino-orbito-cerebral mucormycosis in a patient with aplastic anemia: a case report

    by Pooya Javaherchian, Sogol Alikarami, Masoud Jafarinaasab, Faeze Salahshour, Mohammadreza Salehi, Kamran Roudini, Tahere Yousefi

    Aplastic anemia is a hematologic disorder characterized by bone marrow failure and profound neutropenia, which increases the risk of opportunistic infections such as mucormycosis, an aggressive fungal disease. This condition requires early diagnosis and integrated treatment strategies to reduce the high mortality rate. We report a rare case of rhino-orbito-cerebral mucormycosis in a patient with aplastic anemia. A 16-year-old Middle Eastern (Persian, Iranian) male with a history of aplastic anemia presented with unilateral right-sided facial swelling. He was initially diagnosed with a bacterial soft tissue abscess and treated with antibiotics. Owing to a lack of response, further imaging and histopathological studies were performed, which revealed invasive mucormycosis. The patient received antifungal therapy, but surgical debridement was not performed because of severe thrombocytopenia. His condition deteriorated, and he was admitted to the intensive care unit. Despite resuscitation efforts, the patient died on day 17 of hospitalization. This case highlights the diagnostic and therapeutic challenges in managing mucormycosis in patients with hematological disorders. A key factor contributing to the unfavorable outcome was the prolonged interval between symptom onset and rhino-orbito-cerebral mucormycosis diagnosis. Physicians should consider invasive fungal infections in all immunocompromised patients, particularly those with aplastic anemia, when they present with facial soft tissue infections.

  • Open Access

    Intra‐ and Postoperative Botulinum Toxin Injection in Postsurgical Pain Management: A Literature Review

    by Sogol Alikarami, Saereh Hosseindoost, Ahmad Reza Dehpour, Zahra Rezaei, Hossein Majedi

    Postoperative pain remains a significant challenge in surgical services, which necessitates improving analgesic strategies to enhance patient outcomes. Botulinum neurotoxin (BoNT), which was primarily approved for the treatment of strabismus and blepharospasm, has demonstrated a promising impact on pain reduction through mechanisms such as neurotransmitter inhibition, receptor modulation, glial activity suppression, and interactions with opioidergic and GABAergic systems. A number of studies have investigated BoNT’s impact on postsurgical pain. However, there is a lack of evaluation of its efficacy, safety, and optimal administration protocols across different surgical settings. This study aims to provide a comprehensive overview of the existing literature on the efficacy and complications of intra‐ and postoperative BoNT injections in managing postsurgical pain across various surgical procedures, including orthopedic and head and neck surgeries, mastectomy, hemorrhoidectomy, and fissurectomy.